Phase 3 Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older
- People who have any type of cancer at any stage, are being treated with any type of chemotherapy, and are expected to live at least 6 months or more
- People who have been diagnosed with painful nerve damage caused by chemotherapy, rated at a moderate-to-severe level (Grade 2 or higher), lasting at least 3 months, and who have not started any new pain or nerve treatments in the past month
- People whose average pain score is 3 or higher out of 10 (measured using a standard pain questionnaire), lasting at least 3 months after completing chemotherapy
- Women who could become pregnant must have a negative pregnancy test (blood or urine) before joining, and must agree to use appropriate contraception starting at least 14 days before the first treatment session through to 14 days after the last session
- People who have read, signed, and dated the trial's informed consent form
Who may not be able to join:
- People under 18 years of age
- Women who are pregnant at the time of joining
- Women who could become pregnant but are unwilling to take a pregnancy test or use appropriate contraception during the required period around treatment sessions
- People where there is reason to believe their nerve pain may have been present before chemotherapy due to another cause, such as nerve compression or diabetes, in the same area of the body
- People with a psychiatric illness or personal circumstances that may make it difficult to follow the trial's requirements
- People who are unable to complete the questionnaires used to measure quality of life in the trial
- People with certain liver function test results that are more than 5 times above the normal range (confirm with trial site)
- People with kidney function test results (creatinine) more than 3 times above the normal range
- People who are medically unstable or have a severe illness that is not under control
- People whose cancer is not currently under control
- People whose cancer has spread to the membranes surrounding the brain and spinal cord
- People with a life expectancy of less than 6 months
- People who have a medical reason preventing them from receiving the treatment through rectal administration, or who are unable to attend the scheduled treatment sessions
- People with a known allergy to ozone
- People who do not meet all of the inclusion criteria listed above
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bernardino Clavo, MD, PhD, Dr. Negrín University Hospital, Las Palmas, Spain
Phone: (34)928449278
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change from Baseline in "Average pain" according to the Brief Pain Inventory-Short Form (BPI-SF) (at the end of ozone therapy); Direct Hospital Cost (at the end of ozone therapy)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.